Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1

Oncogene

Volumn 33, Issue 13, 2014, Pages 1690-1699

  Shin, S ^a   Wolgamott, L ^a   Tcherkezian, J ^b   Vallabhapurapu, S ^a   Yu, Y ^c   Roux, P P ^b   Yoon, S O ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

4E BP1; GSK 3; Translation

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INITIATION FACTOR 4E BINDING PROTEIN 1; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EUKARYOTIC CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RNA TRANSLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EUKARYOTA; MAMMALIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL GROWTH PROCESSES; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, NUDE; PEPTIDE INITIATION FACTORS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; RANDOM ALLOCATION; THIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898014860     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.113     Document Type: Article

References (60)

1. Lee J, Kim MS. The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 2007; 77(Suppl 1): S49-S57
2. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11: 539-551
3. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273: 194-200
4. Patel S, Woodgett J. Glycogen synthase kinase-3 and cancer: Good cop, bad cop? Cancer Cell 2008; 14: 351-353
5. Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: Regulation by Wnts and other signaling pathways. Adv Cancer Res 2002; 84: 203-229
6. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3beta. Anticancer Agents Med Chem 2009; 9: 1114-1122
7. Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17: 597-608
8. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205-1209
9. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011; 108: E1204-E1213
10. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007; 110: 735-742
11. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90
12. Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 2002; 12: 1006-1011
13. Qu L, Huang S, Baltzis D, Rivas-Estilla AM, Pluquet O, Hatzoglou M, et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev 2004; 18: 261-277
14. Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychene A, et al. GSK-3-mediated phosphorylation enhances Maf-Transforming activity. Mol Cell 2007; 28: 584-597
15. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, et al. Kinome siRNAphosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-4577
16. Ougolkov AV, Billadeau DD. Targeting GSK-3: A promising approach for cancer therapy? Future Oncol 2006; 2: 91-100
17. Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, et al. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. Mol Cancer Ther 2011; 10: 1460-1469
18. Zeng Q, Yang Z, Gao YJ, Yuan H, Cui K, Shi Y, et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study. Eur J Cancer 2010; 46: 1132-1143
19. Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011; 8: 280-291
20. Mir MA, Panganiban AT. A protein that replaces the entire cellular eIF4F complex. EMBO J 2008; 27: 3129-3139
21. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, et al. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 1999; 13: 1422-1437
22. Ayuso MI, Hernandez-Jimenez M, Martin ME, Salinas M, Alcazar A. New hierarchical phosphorylation pathway of the translational repressor eIF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress. J Biol Chem 2010; 285: 34355-34363
23. Wang X, Proud CG. Methods for studying signal-dependent regulation of translation factor activity. Methods Enzymol 2007; 431: 113-142
24. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15: 2852-2864
25. Wang X, Li W, Parra JL, Beugnet A, Proud CG. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 2003; 23: 1546-1557
26. Tullai JW, Graham JR, Cooper GM. A GSK-3-mediated transcriptional network maintains repression of immediate early genes in quiescent cells. Cell Cycle 2011; 10: 3072-3077
27. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ Res 2002; 90: 1055-1063
28. Eldar-Finkelman H. Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 2002; 8: 126-132
29. Doble BW, Woodgett JR. GSK-3: Tricks of the trade for a multi-Tasking kinase. J Cell Sci 2003; 116: 1175-1186
30. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011; 332: 1322-1326
31. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: It's NOTCH what you think. J Exp Med 2011; 208: 1931-1935
32. Tabares-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J, Valencia A, et al. No paradox, no progress: Inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 2011; 12: 604-608
33. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-Term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-Analysis. JAMA 2008; 300: 2754-2764
34. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6: 103-111
35. Birch NW, Zeleznik-Le NJ. Glycogen synthase kinase-3 and leukemia: Restoring the balance. Cancer Cell 2010; 17: 529-531
36. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431: 200-205
37. Jiang YP, Ballou LM, Lin RZ. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem 2001; 276: 10943-10951
38. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-Type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105: 17414-17419
39. Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012; 11: 594-603
40. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17: 249-261
41. Vinayagam A, Stelzl U, Foulle R, Plassmann S, Zenkner M, Timm J, et al. A directed protein interaction network for investigating intracellular signal transduction. Sci Signal 2011; 4: Rs8
42. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: MTORC2 and beyond. Sci Signal 2009; 2: Pe27
43. Efeyan A, Sabatini DM. mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 2010; 22: 169-176
44. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 2002; 21: 5325-5334
45. Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 2005; 25: 7170-7180
46. Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 2010; 29: 3939-3951
47. Keshwani MM, von Daake S, Newton AC, Harris TK, Taylor SS. Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1). J Biol Chem 2011; 286: 23552-23558
48. Kim GP, Billadeau DD. GSK-3b inhibition in pancreatic cancer. In: Lowy AM, Leach SD, Philip PA (eds). Pancreatic Cancer. Springer: US, 2008, pp 635-646
49. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65: 2076-2081
50. Mishra R. Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol Cancer 2010; 9: 144
51. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, et al. Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophys Res Commun 2005; 334: 1365-1373
52. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-To-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114-127
53. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527
54. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007; 282: 14056-14064
55. Chen Y, Azad MB, Gibson SB. Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol 2010; 88: 285-295
56. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007; 98: 1388-1393
57. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, et al. Deregulated GSK3(beta) sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009; 15: 6810-6819
58. Ikenoue T, Hong S, Inoki K. Monitoring mammalian target of rapamycin (mTOR) activity. Methods Enzymol 2009; 452: 165-180
59. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96
60. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-365.